Close Menu

NEW YORK – Agendia said this week that a German public health insurance fund, Techniker Krankenkasse, will start reimbursing gene expression-based tests for breast cancer patients. Under the fund's contract with the German Pathologists Organization, it will pay for diagnostic tests with the CE mark, including Agendia's MammaPrint test. Agendia said a decision about reimbursement of MammaPrint by all public health insurance funds in Germany is still pending and expected for early 2020.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.